Pfizer reported a strong finish to 2025, delivering Q4 revenue of $17.6 billion and full-year revenue of $62.6 billion. While total revenue declined operationally by 2% for the year, excluding COVID products, operational revenue grew 6% (9% in Q4), driven by double-digit growth in recently launched products like Abrisvo and the Vyndaqel family. Adjusted EPS for the full year was $3.22, beating expectations, with Q4 adjusted EPS reaching $0.66. The company successfully expanded adjusted gross margins to 76% and returned $9.8 billion to shareholders via dividends. Strategically, Pfizer announced positive Phase 2b 'Vespa 3' data for its Metsera-acquired GLP-1 obesity treatment (danuglipron/3944), showing robust weight loss with a differentiated monthly dosing profile. Looking ahead, Pfizer reaffirmed 2026 guidance for revenue of $59.5B-$62.5B and adjusted EPS of $2.80-$3.00, positioning itself for a pivotal investment year to manage upcoming patent cliffs (LOEs) through 2028 while funding a robust pipeline of 20 pivotal studies.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Revenue | $17.6 billion | -3% Operational |
| FY 2025 Revenue | $62.6 billion | -2% Operational |
| Q4 2025 Adjusted EPS | $0.66 | Ahead of Expectations |
| FY 2025 Adjusted EPS | $3.22 | +3.5% vs Prior Year |
| FY 2025 Non-COVID Revenue Growth | N/A | +6% Operational |
| FY 2025 Adjusted Gross Margin | 76% | Expanded |
| 2026 Revenue Guidance | $59.5B - $62.5B | N/A |
| 2026 EPS Guidance | $2.80 - $3.00 | N/A |
Pfizer's obesity strategy received a major validation with the 'Vespa 3' data readout. The study showed that their GLP-1 candidate (danuglipron/3944) achieved 10-12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing. Management believes the monthly maintenance schedule is a key differentiator that will drive patient adherence and market share, potentially offering a 'best-in-class' profile if the predicted 16% weight loss at higher doses is achieved in Phase 3.
The integration of Seagen is progressing 'ahead of expectations,' with Pfizer rapidly advancing the oncology pipeline. Key strategic moves include deprioritizing dicitamab vedotin in bladder cancer to focus resources on PADCEV, which received a new FDA approval. The company is also accelerating the 'SV' ADC program and the '4404' bispecific antibody into Phase 3, signaling a shift from integration to aggressive growth in oncology.
Pfizer is leveraging Artificial Intelligence as a core productivity lever to fund R&D expansion. The company is expanding its GPU capacity to over 1,200 units to accelerate drug discovery and optimize manufacturing. This investment is credited with helping achieve $600 million in manufacturing savings in 2025 and is enabling the launch of 20 pivotal studies in 2026 without increasing R&D spend proportionally.
Capital allocation is increasingly focused on high-growth areas while maintaining the dividend. Pfizer returned $9.8 billion to shareholders in 2025 and reaffirmed its commitment to the dividend. To fund this and the obesity pipeline, the company is pruning non-core assets, including the sale of its stake in the VIVE joint venture and its stake in an HIV joint venture with GSK, redeploying capital into higher-return opportunities like Metsera and 3S Bio.
Pfizer faces significant near-term revenue headwinds from the Loss of Exclusivity (LOE) cliff starting in 2026. Guidance for 2026 implies a revenue decline to the mid-$60 billions at best, with adjusted EPS dropping to a range of $2.80-$3.00. Management acknowledged that leverage will remain at current levels or slightly higher through this period, limiting financial flexibility for further large M&A.
The company recorded a substantial $4.4 billion non-cash impairment charge in Q4 related to intangible assets, specifically citing the deprioritization of dicitamab vedotin. While management frames this as 'prioritization,' it represents a significant write-down of value from the Seagen acquisition and internal pipeline, raising questions about the valuation of acquired assets.
CEO Albert Bourla definitively shut down any speculation regarding a lifecycle management strategy for Vyndaqel, stating, 'Right now, we are assuming that the patent will be lost in 2028. And I don't have any other comments to make on that.' This removes a potential upside lever for investors and confirms a sharp revenue drop-off for this key product in the near future.
Despite the positive obesity data, Pfizer is entering a crowded market late. With first approvals not expected until 2028, Pfizer will be competing against established leaders like Novo Nordisk and Eli Lilly. The success of their 'monthly' differentiator is critical, as the weight loss numbers (10-12%) are currently competitive but not clearly superior to existing weekly therapies.
Overall: Management displayed a high level of confidence and enthusiasm, frequently characterizing 2025 as a 'very good year' and Q4 results as 'stellar.' The tone shifted from defensive regarding COVID declines to offensive regarding the company's execution capabilities and future pipeline potential. Executives were detailed and data-driven, particularly when discussing the obesity and oncology pipelines, suggesting a strong belief in their strategic pivot.
Confidence: HIGH - Management consistently used strong, definitive language regarding past execution ('overdeliver', 'stellar') and future potential ('confident', 'compelling'). The reaffirmation of 2026 guidance despite significant LOE headwinds, coupled with specific scientific data points to support their obesity claims, indicates a high degree of certainty in their strategy.
$59.5 billion to $62.5 billion
$2.80 to $3.00 per share
Approximately $5.0 billion
Approximately 4% operational growth
Hedging & Uncertainty: Management used minimal hedging when discussing past financial performance, utilizing strong terms like 'overdeliver,' 'stellar,' and 'exceeded expectations.' However, standard probabilistic hedging was employed regarding future pipeline milestones, using phrases like 'potential to deliver,' 'anticipated,' and 'expected.' Notably, when discussing the obesity data, Chris Boshoff shifted from hedging to more definitive language ('We are confident,' 'robust statistically significant') to validate the science, while Albert Bourla used definitive language ('will be lost') to shut down questions about Vyndaqel patents.
2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. - Albert Bourla, Chairman and CEO
We are confident that 3944 has the potential to deliver efficacy that is competitive with the standard of care and potentially best in class among monoagonists. - Chris Boshoff, Chief Scientific Officer
Right now, we are assuming that the patent will be lost in 2028. And I don't have any other comments to make on that. - Albert Bourla, Chairman and CEO
We are on track to deliver the majority of the anticipated $7.2 billion in total net cost savings from our productivity programs by 2026. - Dave Denton, CFO
The VASPER three phase 2b study was designed to evaluate 3944 with monthly maintenance dosing... I'm pleased to share that we observed robust statistically significant weight loss across all doses tested. - Chris Boshoff, Chief Scientific Officer
Analyst Sentiment: Analysts were highly engaged, with the majority of questions focusing on the newly released obesity data (Vespa 3). There was a clear focus on understanding the competitive positioning of monthly dosing versus weekly therapies and the tolerability profile of the higher doses.
Management Responses: Management was well-prepared and detailed. Chris Boshoff provided deep scientific context to defend the efficacy and safety data, while commercial leaders Aamir Malik and Alexandre de Germay articulated a clear market strategy focusing on out-of-pocket penetration ex-US. Albert Bourla was direct and firm on patent questions, signaling a no-nonsense approach to guidance.
Obesity (Vespa 3): Detailed discussion on weight loss efficacy (10-12.3%), monthly dosing logistics, tolerability (GI events), and the potential for the high dose (9.6mg) to reach 16% weight loss.
Oncology (Seagen): Updates on the integration progress, the acceleration of the 'SV' and '4404' programs, and the strategic deprioritization of dicitamab vedotin in favor of PADCEV.
Capital Allocation: Clarification on the dividend strategy, the use of proceeds from the VIVE stake sale, and the capacity for Business Development (~$7B).
AI & Productivity: Discussion on the ROI of AI investments, specifically regarding manufacturing savings and R&D productivity gains.
Pfizer's Q4 2025 earnings call signaled a successful transition from a pandemic-dependent company to a diversified growth engine. The 'stellar' operational execution, which allowed them to beat EPS estimates despite the COVID cliff, demonstrates management's discipline. The positive Vespa 3 data de-risks the Metsera acquisition and establishes Pfizer as a legitimate contender in the massive obesity market with a differentiated monthly dosing profile. While 2026 faces headwinds from LOEs, the company's robust cost savings program ($7.2B target) and the impending launch of 20 pivotal studies suggest a strong setup for late-decade growth. The combination of a fortified dividend, a deepening oncology pipeline (Seagen), and a breakthrough obesity platform provides a compelling risk-reward balance for long-term investors.
Management highlighted that the global obesity market is projected to reach $150 billion, with 40% of the market located outside the US. They noted a surprisingly high 'willingness to pay out-of-pocket' in international markets ($250-$350 per month), which suggests faster market penetration and less pricing pressure than typical reimbursement-dependent drugs.
The discussion around the Vyndaqel patent cliff (2028) and the lack of any strategy to extend it highlights the persistent threat of generic erosion and the difficulty of defending patents against complex legal challenges in the current environment.